Cargando…
No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland
BACKGROUND: Narcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02. A sudden increase in the incidence of childhood narcolepsy was observed after vaccination with AS03-adjuvant...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738560/ https://www.ncbi.nlm.nih.gov/pubmed/23950869 http://dx.doi.org/10.1371/journal.pone.0068402 |
_version_ | 1782476861863886848 |
---|---|
author | Melén, Krister Partinen, Markku Tynell, Janne Sillanpää, Maarit Himanen, Sari-Leena Saarenpää-Heikkilä, Outi Hublin, Christer Olsen, Päivi Ilonen, Jorma Nohynek, Hanna Syrjänen, Ritva Kilpi, Terhi Vuorela, Arja Kirjavainen, Turkka Vaarala, Outi Julkunen, Ilkka |
author_facet | Melén, Krister Partinen, Markku Tynell, Janne Sillanpää, Maarit Himanen, Sari-Leena Saarenpää-Heikkilä, Outi Hublin, Christer Olsen, Päivi Ilonen, Jorma Nohynek, Hanna Syrjänen, Ritva Kilpi, Terhi Vuorela, Arja Kirjavainen, Turkka Vaarala, Outi Julkunen, Ilkka |
author_sort | Melén, Krister |
collection | PubMed |
description | BACKGROUND: Narcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02. A sudden increase in the incidence of childhood narcolepsy was observed after vaccination with AS03-adjuvanted Pandemrix influenza vaccine in Finland at the beginning of 2010. Here, we analysed whether the coinciding influenza A H1N1pdm pandemic contributed, together with the Pandemrix vaccination, to the increased incidence of childhood narcolepsy in 2010. The analysis was based on the presence or absence of antibody response against non-structural protein 1 (NS1) from H1N1pdm09 virus, which was not a component of Pandemrix vaccine. METHODS: Non-structural (NS) 1 proteins from recombinant influenza A/Udorn/72 (H3N2) and influenza A/Finland/554/09 (H1N1pdm09) viruses were purified and used in Western blot analysis to determine specific antibody responses in human sera. The sera were obtained from 45 patients who fell ill with narcolepsy after vaccination with AS03-adjuvanted Pandemrix at the end of 2009, and from controls. FINDINGS: Based on quantitative Western blot analysis, only two of the 45 (4.4%) Pandemrix-vaccinated narcoleptic patients showed specific antibody response against the NS1 protein from the H1N1pdm09 virus, indicating past infection with the H1N1pdm09 virus. Instead, paired serum samples from patients, who suffered from a laboratory confirmed H1N1pdm09 infection, showed high levels or diagnostic rises (96%) in H1N1pdm virus NS1-specific antibodies and very high cross-reactivity to H3N2 subtype influenza A virus NS1 protein. CONCLUSION: Based on our findings, it is unlikely that H1N1pdm09 virus infection contributed to a sudden increase in the incidence of childhood narcolepsy observed in Finland in 2010 after AS03-adjuvanted Pandemrix vaccination. |
format | Online Article Text |
id | pubmed-3738560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37385602013-08-15 No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland Melén, Krister Partinen, Markku Tynell, Janne Sillanpää, Maarit Himanen, Sari-Leena Saarenpää-Heikkilä, Outi Hublin, Christer Olsen, Päivi Ilonen, Jorma Nohynek, Hanna Syrjänen, Ritva Kilpi, Terhi Vuorela, Arja Kirjavainen, Turkka Vaarala, Outi Julkunen, Ilkka PLoS One Research Article BACKGROUND: Narcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02. A sudden increase in the incidence of childhood narcolepsy was observed after vaccination with AS03-adjuvanted Pandemrix influenza vaccine in Finland at the beginning of 2010. Here, we analysed whether the coinciding influenza A H1N1pdm pandemic contributed, together with the Pandemrix vaccination, to the increased incidence of childhood narcolepsy in 2010. The analysis was based on the presence or absence of antibody response against non-structural protein 1 (NS1) from H1N1pdm09 virus, which was not a component of Pandemrix vaccine. METHODS: Non-structural (NS) 1 proteins from recombinant influenza A/Udorn/72 (H3N2) and influenza A/Finland/554/09 (H1N1pdm09) viruses were purified and used in Western blot analysis to determine specific antibody responses in human sera. The sera were obtained from 45 patients who fell ill with narcolepsy after vaccination with AS03-adjuvanted Pandemrix at the end of 2009, and from controls. FINDINGS: Based on quantitative Western blot analysis, only two of the 45 (4.4%) Pandemrix-vaccinated narcoleptic patients showed specific antibody response against the NS1 protein from the H1N1pdm09 virus, indicating past infection with the H1N1pdm09 virus. Instead, paired serum samples from patients, who suffered from a laboratory confirmed H1N1pdm09 infection, showed high levels or diagnostic rises (96%) in H1N1pdm virus NS1-specific antibodies and very high cross-reactivity to H3N2 subtype influenza A virus NS1 protein. CONCLUSION: Based on our findings, it is unlikely that H1N1pdm09 virus infection contributed to a sudden increase in the incidence of childhood narcolepsy observed in Finland in 2010 after AS03-adjuvanted Pandemrix vaccination. Public Library of Science 2013-08-08 /pmc/articles/PMC3738560/ /pubmed/23950869 http://dx.doi.org/10.1371/journal.pone.0068402 Text en © 2013 Melén et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Melén, Krister Partinen, Markku Tynell, Janne Sillanpää, Maarit Himanen, Sari-Leena Saarenpää-Heikkilä, Outi Hublin, Christer Olsen, Päivi Ilonen, Jorma Nohynek, Hanna Syrjänen, Ritva Kilpi, Terhi Vuorela, Arja Kirjavainen, Turkka Vaarala, Outi Julkunen, Ilkka No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title | No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title_full | No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title_fullStr | No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title_full_unstemmed | No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title_short | No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland |
title_sort | no serological evidence of influenza a h1n1pdm09 virus infection as a contributing factor in childhood narcolepsy after pandemrix vaccination campaign in finland |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738560/ https://www.ncbi.nlm.nih.gov/pubmed/23950869 http://dx.doi.org/10.1371/journal.pone.0068402 |
work_keys_str_mv | AT melenkrister noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT partinenmarkku noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT tynelljanne noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT sillanpaamaarit noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT himanensarileena noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT saarenpaaheikkilaouti noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT hublinchrister noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT olsenpaivi noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT ilonenjorma noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT nohynekhanna noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT syrjanenritva noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT kilpiterhi noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT vuorelaarja noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT kirjavainenturkka noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT vaaralaouti noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland AT julkunenilkka noserologicalevidenceofinfluenzaah1n1pdm09virusinfectionasacontributingfactorinchildhoodnarcolepsyafterpandemrixvaccinationcampaigninfinland |